Tumor necrosis factor-α inhibitors (TNFis) have transformed care for rheumatoid arthritis and other autoimmune diseases, but they also are associated with higher risks of serious and opportunistic infections than traditional disease-modifying antirheumatic drugs. In this article, Cassandra Calabrese, DO, discusses balancing the benefits of biologic therapies with the risks of infection.
Is it idiopathic psoriasis or TNFi-induced psoriasis? A new study finds histological differences between these two types of psoriatic lesions that impact treatment.
Women with rheumatoid arthritis who are of childbearing age face many challenges throughout pregnancy and extending into the postpartum period, from fertility to birth outcomes and control of disease. In this article, rheumatologist Emily Littlejohn, DO, MPH, discusses special considerations for managing patients with rheumatoid arthritis throughout pregnancy and the postpartum period.
Cleveland Clinic’s Rheumatic Lung Disease Program is currently engaged in three major multicenter trials whose common aim is to improve outcomes for patients with rheumatic disease and pulmonary hypertension or interstitial lung disease.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
If it’s been a while since you last worked your way through basic and clinical immunologic principles as they apply to diagnosis, treatment and pathogenesis of autoimmune and autoinflammatory diseases, Clinical Immunology Boot Camp is for you.
Subgroup analyses from the PRECISION trial allow rheumatologists to offer individualized treatment to OA and RA patients on chronic NSAIDs.
The promise of drug-free RA remission is appealing, but many questions remain. Explore answers at Biologics Summit VII in April 2017.
Advances in genetics, biologics and understanding of environmental factors are getting us closer to preventing RA in susceptible patients.